Full-Time

Key Account Specialist

Multiple Myeloma Sales

Updated on 9/12/2026

Deadline 9/18/26
Sanofi

Sanofi

10,001+ employees

Global pharma company; vaccines and R&D

Compensation Overview

CA$107.8k - CA$157.8k/yr

+ Bonuses + Company car

Montreal, QC, Canada + 2 more

More locations: Laval, QC, Canada | Québec City, QC, Canada

Remote

The role covers western Quebec, Newfoundland and Labrador, with travel approximately 60% of the time.

Bachelor's

Category
Sales & Account Management (1)
Required Skills
CRM

Get referred to Sanofi

See people who can refer or advise you

Requirements
  • A Bachelor's degree in Science, Business, or a related field is required.
  • More than 5 years of specialty pharmaceutical sales experience is required, with oncology or hematology experience strongly preferred.
  • A demonstrated track record of high performance in complex, specialist-driven markets is required.
  • A strong understanding of Hematology/Oncology, including treatment landscapes, patient journeys, and market access, is required.
  • Experience with institutional accounts, reimbursement processes, and formulary approvals is required.
  • The candidate must be able to interpret market data and translate insights into action.
  • The candidate must have consultative, value-based selling and account strategy execution experience.
  • The candidate must be able to influence without authority and lead through collaboration across cross-functional teams.
  • The candidate must be able to translate complex clinical information into meaningful conversations with senior clinical stakeholders.
  • The candidate must be able to develop strong fluency in disease state, clinical data, and product complexity.
  • The candidate must have planning, prioritization, and territory management skills.
  • The candidate must be self-directed and comfortable working independently in a field-based environment with a high degree of ownership.
  • The candidate must be proficient with customer relationship management systems and digital engagement tools.
  • Fluency in both French and English is required.
  • The candidate must be willing and able to travel approximately 60% of the time, including national and occasional international travel.
  • The candidate must have flexibility to work evenings and weekends as required by business needs.
  • The candidate must be eligible for a company vehicle and maintain an acceptable driving record after completing required fleet safety training.
Responsibilities
  • Meet or exceed sales and performance objectives while managing territory resources responsibly.
  • Develop, execute, and continuously refine a data-driven territory business plan incorporating market dynamics, customer insights, and brand strategy.
  • Identify risks and opportunities and adjust the approach to protect and grow business results.
  • Analyze market trends, customer needs, and competitive insights to inform strategy and identify new growth opportunities.
  • Build and maintain value-based partnerships with hematologic oncologists, nurses, pharmacists, and key allied health professionals.
  • Serve as the primary commercial contact for Sanofi within assigned accounts and coordinate cross-functional support from Marketing, Medical, Patient Support, and other internal partners.
  • Understand account decision-making structures and adapt the engagement approach accordingly.
  • Support institutions and key accounts by guiding formulary and budget approval processes.
  • Conduct scientific exchanges aligned with the Product Monograph and Sanofi's ethical and compliance standards.
  • Explain the clinical and patient value of Sanofi therapies within evolving Multiple Myeloma treatment paradigms.
  • Educate and train healthcare teams on the clinical benefits, administration, and real-world use of Sanofi therapies.
  • Facilitate peer-to-peer learning between community-based and academic oncologists to optimize Multiple Myeloma treatment pathways.
  • Build meaningful local advocacy through consistent, credible relationships with key stakeholders.
  • Support regional and national educational programs, learning initiatives, and congresses.
  • Maintain a current and accurate territory and account database to inform national planning and execution.
  • Use omnichannel and digital tools to enhance customer engagement and drive impactful conversations.
  • Execute all activities in alignment with Sanofi's regulatory, legal, and compliance standards.
  • Maintain accurate customer relationship management documentation, call reporting, expense management, and other administrative records.
  • Complete mandatory training and steward company assets.
  • Participate in national and regional meetings, conferences, and training programs.
Desired Qualifications
  • Oncology or Hematology specialty pharmaceutical sales experience is strongly preferred.

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 sales rose 13.6%, while launches grew 49.6% and Dupixent 30.8%.
  • July 2026 FDA approval expanded Sarclisa across all U.S. myeloma indications.
  • Paulo Fontoura assumed R&D leadership on September 1, 2026, accelerating pipeline execution.

What critics are saying

  • Tolebrutinib’s FDA rejection on December 24, 2025 exposed severe liver-injury risk.
  • Dupixent lawsuits consolidated in New Jersey by June 2026 threaten label and damages exposure.
  • Sanofi’s insulin plant needed €400 million German aid on September 8, 2026, signaling supply fragility.

What makes Sanofi unique

  • Dupixent posted €4.17 billion Q1 2026 sales, dominating immunology globally.
  • Sanofi’s July 2026 Sarclisa Escena became the first cancer on-body injector treatment.
  • Sanofi secured Cenrifki EU approval in June 2026, advancing a differentiated MS franchise.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

La Croix
Sep 8th, 2026
EU approves $448M German subsidy to Sanofi for insulin production security

The European Commission has approved a €400 million subsidy from Germany to pharmaceutical company Sanofi to maintain its Frankfurt insulin production site. The Commission stated that without this aid, Sanofi would close the German facility, reducing insulin supply security across the European Economic Area. The subsidy aims to compensate Sanofi for costs related to a service of general economic interest, strengthening insulin supply resilience for German patients. In return, Sanofi must build a new insulin factory in Frankfurt by 31 December 2032 and guarantee minimum annual production of 1.1 tonnes until 2042. Sanofi is among the world's leading insulin producers. The company announced in 2024 a €1.3 billion investment in Frankfurt to construct a new complex replacing existing facilities.

StreetInsider
Aug 25th, 2026
Altesa BioSciences wins award for oversubscribed $75M Series B to advance COPD therapies

Atlanta-based Altesa BioSciences has won the 2026 Georgia Life Sciences Golden Helix Award for Deal of the Year, recognising its oversubscribed $75 million Series B financing round. The funding, led by Forbion with participation from Sanofi, Medicxi, Pitango, and Atlantic Partners, will advance the clinical-stage pharmaceutical company's lead therapy, vapendavir. Vapendavir is an investigational oral treatment for chronic lung diseases including COPD and asthma. The drug is currently being evaluated in the Phase 2b CARDINAL trial, which will enrol 900 COPD patients across the US and UK. The Georgia Research Alliance Venture Fund was an early investor in Altesa. The company's scientific founders previously helped develop molnupiravir, one of the earliest COVID-19 treatments.

Business Wire
Aug 13th, 2026
Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Epicrispr Biotechnologies Closes $90 Million Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Morningstar
Aug 12th, 2026
InduPro raises $77M Series B, doses first patient in Phase 1 trial of bispecific ADC for lung cancer

InduPro has closed a $77 million Series B financing round and dosed its first patient in a Phase 1 study of IDP-001, its lead oncology programme. The biotechnology company is developing IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen, for treating advanced squamous non-small cell lung cancer and other solid tumours. The Column Group led the financing round, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Proceeds will support Phase 1 clinical development and early proof-of-concept data generation for IDP-001, whilst advancing InduPro's broader preclinical pipeline. InduPro uses a proximity-guided platform to map protein spatial relationships on cell surfaces for discovering selective co-target pairs.

FinancialContent
Jul 24th, 2026
Scribe Therapeutics prices upsized $129M IPO at top of range

Scribe Therapeutics, a clinical-stage biotechnology company developing in vivo CRISPR technologies, has priced its upsized initial public offering at $15.00 per share, the high end of its range. The company is offering 8,580,000 shares, expecting to raise $128.7 million in gross proceeds before fees and expenses. Scribe has also granted underwriters a 30-day option to purchase up to 1,287,000 additional shares. The shares are expected to begin trading on the Nasdaq Global Market on 24 July 2026 under the ticker symbol "SCTX", with the offering closing on 27 July 2026. Additionally, Scribe has agreed to sell 500,000 shares at the same price to Sanofi in a concurrent private placement. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers.